Search Result
Results for "
SGC
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-112445
-
SGC3027
3 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
SGC3027 is a histone methyltransferase inhibitor . SGC3027 is the first potent, selective and cell active chemical probe for PRMT7 .
|
-
-
- HY-122186
-
-
-
- HY-126300A
-
|
Histone Methyltransferase
|
Cancer
|
SGC6870N is inactive against PRMT6 and can be utilized as a negative control. SGC6870N is an inactive enantiomer of SGC6870 (HY-126300) .
|
-
-
- HY-155697
-
|
HDAC
|
Cancer
|
SGC-UBD253 is a potent HDAC6-UBD antagonist. SGC-UBD253 can be used in research of cancer .
|
-
-
- HY-142697
-
|
Others
|
Cardiovascular Disease
|
SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A) .
|
-
-
- HY-100565
-
SGC2085
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
SGC2085 is a potent and selective inhibitor of coactivator associated arginine methyltransferase 1 (CARM1) with an IC50 of 50 nM. SGC2085 also selectively inhibits PRMT6 with an IC50 value of 5.2 μM, but not other PRMT proteins .
|
-
-
- HY-100565A
-
|
Histone Methyltransferase
|
|
SGC2085 hydrochloride is a potent and selective inhibitor of coactivator associated arginine methyltransferase 1 (CARM1) with an IC50 of 50 nM. SGC2085 hydrochloride also selectively inhibits PRMT6 with an IC50 value of 5.2 μM, but not other PRMT proteins .
|
-
-
- HY-15650
-
|
Histone Methyltransferase
|
Cancer
|
SGC0946 is a selective DOT1LH3K79 methyltransferase) inhibitor, with an IC50 of 0.3 nM. SGC0946 results in G1 arrest, inhibits potential of cell self-renewal and metastatic, also induces cell differentiation. SGC0946 can be used in studies of leukemia and solid tumors and also serve as a probe to further investigate the cellular mechanism of DOT1L in both normal and diseased cells .
|
-
-
- HY-126300
-
-
-
- HY-123940
-
|
AAK1
|
Cancer
|
SGC-AAK1-1 is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor with an IC50 of 270 nM and a Ki of 9 nM. SGC-AAK1-1 also potently inhibits BMP2K. SGC-AAK1-1 is used to study Wnt pathway related to AAK1 .
|
-
-
- HY-142698
-
|
Others
|
Cardiovascular Disease
|
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
|
-
-
- HY-145446
-
|
Epigenetic Reader Domain
|
Metabolic Disease
|
SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2/4 and PB1(5), with Kds of 35 nM, 36 nM, and 13 nM, respectively. SGC-SMARCA-BRDVIII also inhibits PB1(2) and PB1(3), with Kds of 3.7 and 2.0 μM, respectively. SGC-SMARCA-BRDVIII can block adipogenesis of 3T3-L1 murine fibroblasts .
|
-
-
- HY-112804
-
|
Epigenetic Reader Domain
|
Cancer
|
SGC-iMLLT is a first-in-class chemical probe and a potent, selective inhibitor of MLLT1/3-histone interactions with an IC50 of 0.26 μM. SGC-iMLLT shows high binding activity towards MLLT1 YEATS domain (YD) and MLLT3 YD (AF9/YEATS3) with Kds of 0.129 and 0.077 μM, respectively .
|
-
-
- HY-19715
-
-
-
- HY-160065
-
|
Others
|
Cancer
|
sgc8c aptamer sodium is an aptamer that specifically targets the human protein tyrosine kinase PTK-7, which is mainly expressed on cervical cancer HeLa cells. Binding of sgc8c aptamer sodium to PTK-7 induces the assembly of nanotags on the cell surface, resulting in strong fluorescence and SERS signals. Specific to cervical cancer cells .
|
-
-
- HY-15826
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Inflammation/Immunology
Cancer
|
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
|
-
-
- HY-139004
-
|
Casein Kinase
|
Neurological Disease
|
SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases .
|
-
-
- HY-156350
-
|
Others
|
Cancer
|
SGC-STK17B-1 is an ATP-competitive and selective STK17B inhibitor (IC50: 34 nM, KD: 5.6 nM) .
|
-
-
- HY-147083
-
|
AAK1
|
Cancer
|
SGC-AAK1-1N is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor, with an IC50 of 1.8 μM .
|
-
-
- HY-17500
-
HMR-1766
|
Guanylate Cyclase
|
Cardiovascular Disease
|
Ataciguat (HMR-1766) is a nitric oxide-independent soluble guanylate cyclase (sGC) activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects .
|
-
-
- HY-111516
-
-
-
- HY-107546
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases .
|
-
-
- HY-117917
-
-
-
- HY-W062836
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research .
|
-
-
- HY-19714
-
XY1
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
XY1 is an analog of SGC707 (SGC707 is a potent, selective PRMT3 inhibitor with an IC50 value of 31 nM), but XY1 is completely inactive against PRMT3.
|
-
-
- HY-109066
-
IW-1701
|
Guanylate Cyclase
|
Cardiovascular Disease
|
Olinciguat (IW-1701) is an oral guanylate cyclase (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay .
|
-
-
- HY-N10201
-
|
Endogenous Metabolite
|
Cancer
|
Cytoglobosin C, a cytochalasan derivative, shows potent cytotoxicity against both SGC-7901 and A549 cell lines (IC50<10 μM) .
|
-
-
- HY-117962
-
|
Guanylate Cyclase
|
Metabolic Disease
|
(Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy .
|
-
-
- HY-113926
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect .
|
-
-
- HY-N7980
-
|
NF-κB
|
Cancer
|
Rubipodanone A, a naphthohydroquinone dimer, shows cytotoxicity against A549, BEL-7402, HeLa, HepG2, SGC-7901 and U251 cells. Rubipodanone A also shows obvious activating effect at 20 and 40 μM for NF-κB .
|
-
-
- HY-14181
-
-
-
- HY-12376
-
|
Guanylate Cyclase
|
Inflammation/Immunology
|
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
|
-
-
- HY-N1841
-
3'-Hydroxyrocaglamide
|
|
|
Rocaglamide D (3'-Hydroxyrocaglamide) (compound 1) is a lignan that can be found in Aglaia odorata. Rocaglamide D shows cytotoxicity with IC50s of 0.32, 0.12, 0.25 µM for HeLa, SGC-7901, A549 cells, respectively .
|
-
-
- HY-14779
-
-
-
- HY-161351
-
|
Akt
STAT
Apoptosis
|
Cancer
|
STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .
|
-
-
- HY-N9046
-
|
NO Synthase
|
Inflammation/Immunology
Cancer
|
Citroside A is a megastigmane sesquiterpenoid with cytotoxic and anti-inflammatory activities. Citroside A displays potential effects against NO production with an IC50 of 34.25 μM. Citroside A exhibits pronounced cytotoxicity against SGC-7901 and HeLa cells with IC50 values of 27.52 μM and 29.51 μM, respectively .
|
-
-
- HY-133083
-
|
c-Met/HGFR
|
Cancer
|
BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe .
|
-
-
- HY-155360
-
|
YAP
Apoptosis
|
Cancer
|
MY-1076 is an inhibitor of YAP. MY-1076 induces YAP degradation and cell apoptosis. MY-1076 inhibits MGC-803, SGC-7901, HCT-116 and KYSE450 cells proliferation with IC50 s of 0.019, 0.017, 0.020 and 0.044 μM, respectively .
|
-
-
- HY-14927
-
Lificiguat
Maximum Cited Publications
18 Publications Verification
YC-1
|
Guanylate Cyclase
|
Cancer
|
Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.
|
-
-
- HY-W015084
-
|
Apoptosis
|
Cancer
|
β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity .
|
-
-
- HY-W013386
-
-
-
- HY-156098
-
|
c-Met/HGFR
|
Cancer
|
c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC50s of 0.25, 0.36, 0.98, 0.76 μM .
|
-
-
- HY-117962A
-
|
Guanylate Cyclase
|
Metabolic Disease
|
BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat .
|
-
-
- HY-107548
-
|
Biochemical Assay Reagents
|
Others
|
A-350619 hydrochloride is a soluble guanylate cyclase (sGC) activator. A-350619 hydrochloride can be used in the study of erectile dysfunction .
|
-
-
- HY-146311
-
|
Microtubule/Tubulin
|
Cancer
|
Tubulin polymerization-IN-16 (compound 5g) is a potent inhibitor of tubulin polymerization. Tubulin polymerization-IN-16 shows most potent against cancer cells, with IC50 values of 0.084-0.221 μM. Tubulin polymerization-IN-16 potently disrupts microtubule/tubulin dynamics, induces cell cycle arrest at G2/M phase in SGC-7901 cells .
|
-
-
- HY-101255
-
ODQ
2 Publications Verification
|
|
|
ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .
|
-
-
- HY-147947
-
|
Microtubule/Tubulin
|
Cancer
|
Tubulin polymerization-IN-30 (compound 6e) is a potent Tubulin polymerization inhibitor. Tubulin polymerization-IN-30 is a colchicine binding site inhibitor. Tubulin polymerization-IN-30 can disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. Tubulin polymerization-IN-30 exhibits the high potency against the cancer cell lines including SGC-7901, A549 and HeLa, with IC50 values of 2.16, 2.21, and 0.403 μM .
|
-
-
- HY-14779S
-
BAY 632521-13C,d6
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
Riociguat- 13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
|
-
-
- HY-109039
-
IW-1973
|
Guanylate Cyclase
|
Cardiovascular Disease
|
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC50 of 197 nM .
|
-
-
- HY-W015084S
-
|
Isotope-Labeled Compounds
Apoptosis
|
Cancer
|
β-Ionone- 13C3 is the 13C-labeled β-Ionone. β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity[1].
|
-
- HY-111457A
-
|
Elastase
|
Inflammation/Immunology
|
BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
|
-
- HY-W015084A
-
β-Lonone
|
Apoptosis
|
Cancer
|
(E)-β-Ionone is the isomer of β-Ionone (HY-W015084). β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. β-Ionone has anti-cancer activity .
|
-
- HY-117604
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species .
|
-
- HY-153092
-
BI-685509
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
|
-
- HY-153788
-
|
Casein Kinase
|
Cancer
|
CK2-IN-7 (compound 2) is an inhibitor of casein kinase 2 (CK2). CK2-IN-7 shows synergistic effect with structurally distinct CK2 chemical probe: SGC-CK2-1, against cancer .
|
-
- HY-111515
-
|
Elastase
|
Inflammation/Immunology
|
BAY-678 racemate is a racemate of BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
|
-
- HY-111457
-
|
Others
|
Inflammation/Immunology
|
BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
|
-
- HY-B1359
-
C.I. Basic Blue 9 trihydrate
|
|
|
Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment .
|
-
- HY-153369
-
|
Guanylate Cyclase
|
Cardiovascular Disease
Neurological Disease
|
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
|
-
- HY-14536
-
Basic Blue 9; CI-52015; Methylthioninium chloride
|
Guanylate Cyclase
Monoamine Oxidase
NO Synthase
Microtubule/Tubulin
|
Infection
Neurological Disease
Cancer
|
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
|
-
- HY-D0958
-
Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate
|
Guanylate Cyclase
Monoamine Oxidase
NO Synthase
Microtubule/Tubulin
|
Infection
Inflammation/Immunology
Cancer
|
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
|
-
- HY-12379
-
|
Guanylate Cyclase
|
Inflammation/Immunology
|
NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity . NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM . NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM . NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM) . NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-14536
-
Basic Blue 9; CI-52015; Methylthioninium chloride
|
Chromogenic Assays
|
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14779S
-
|
Riociguat- 13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
|
-
-
- HY-W015084S
-
|
β-Ionone- 13C3 is the 13C-labeled β-Ionone. β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity[1].
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P82402
-
GCbeta1; GCS beta 1; GCS beta 3; GUC1B3; GUCSB3; GUCY1B1; Gucy1b1; GUCY1B3; SGC
|
WB, IHC-P
|
Human, Mouse, Rat |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: